Key result
Rosiglitazone treatment for 4 months in overweight women with PCOS significantly increased plasma adiponectin (P<0.001) and decreased resistin levels (P=0.009).
Why the study?
Does rosiglitazone improve plasma levels of adiponectin, resistin, and ghrelin in overweight women with PCOS?
Population
30 overweight/obese women with polycystic ovary syndrome (PCOS), BMI >25 kg/m², mean age 29.1+/-1.2 years
Comparison
Rosiglitazone 4 mg oral twice a day for 4 months vs Placebo
Design
RCT, Randomly allocated, Placebo-controlled
Follow-up
4 months
Authors
Loading...
May support insulin sensitivity gains in PCOS; confirms adipokine effects in this RCT.
RCT (n=30)
randomly allocated
Does rosiglitazone improve plasma levels of adiponectin, resistin, and ghrelin in overweight women with PCOS?
p-value: p=<0.001
Rosiglitazone treatment for 4 months significantly increases adiponectin and decreases resistin levels in overweight women with PCOS, which may contribute to improved insulin sensitivity.
Majuri et al. (2007) conducted an RCT in polycystic ovary syndrome (PCOS) (n=30). Rosiglitazone vs. placebo was evaluated on Plasma levels of adiponectin (p=<0.001). Rosiglitazone treatment for 4 months in overweight women with PCOS significantly increased plasma adiponectin (P<0.001) and decreased resistin levels (P=0.009).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: